Results 11 to 20 of about 830,210 (192)

“Clicking“ fragment leads to novel dual-binding cholinesterase inhibitors [PDF]

open access: yes, 2021
Cholinesterase inhibitors are potent therapeutics in the treatment of Alzheimer's disease. Among them, dual binding ligands have recently gained a lot of attention.
Czarnocki, Zbigniew   +14 more
core   +1 more source

Plant Terpenoids as the Promising Source of Cholinesterase Inhibitors for Anti-AD Therapy [PDF]

open access: yes, 2022
Plant-derived terpenes are the prolific source of modern drugs such as taxol, chloroquine and artemisinin, which are widely used to treat cancer and malaria infections.
Min, Shereen Lai Shi   +11 more
core   +1 more source

Previous studies of correlation of neuroanatomical markers and response of cholinesterase inhibitors in Alzheimer’s disease.

open access: yes, 2023
Previous studies of correlation of neuroanatomical markers and response of cholinesterase inhibitors in Alzheimer’s disease.
Chia-Ju Chou (14611466)   +5 more
core   +1 more source

Impact of cholinesterase inhibitors on behavioural and psychological symptoms of Alzheimer's disease: A meta-analysis [PDF]

open access: yes, 2008
Noll Campbell1, Amir Ayub2, Malaz A Boustani2, Chris Fox3, Martin Farlow4, Ian Maidment3, Robert Howard51Wishard Health Services, Indianapolis, Indiana; 2Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, Indiana ...
Campbell, Noll   +13 more
core   +1 more source

Top adverse effects for cholinesterase inhibitors in FAERS database.

open access: yes, 2016
Top adverse effects for cholinesterase inhibitors in FAERS database.
Winston Yuchen Chen (834602)   +4 more
core   +1 more source

Cholinesterase inhibitors in advanced dementia with Lewy bodies: increase or stop?

open access: yes, 2006
INTRODUCTION There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB.
Pakrasi, Sanjeet   +17 more
core   +1 more source

Honeys as Possible Sources of Cholinesterase Inhibitors

open access: yes, 2022
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by low levels of the neurotransmitter (acetylcholine), oxidative stress, and inflammation of the central nervous system.
Dominik Szwajgier   +7 more
core   +1 more source

Potential revival of cholinesterase inhibitors as drugs in veterinary medicine

open access: yes, 2023
The cholinergic system is involved in the regulation of all organ systems and has acetylcholine (ACh) as almost its only neurotransmitter. Any substance is called cholinergic if it can alter the action of acetylcholine. Cholinesterases (ChEs) are enzymes
Štrbenc, Malan   +7 more
core   +1 more source

TRAIP Mediates Alcohol‐Induced Liver Injury through Regulating β‐catenin Ubiquitin Degradation via Direct Interaction

open access: yesAdvanced Science, EarlyView.
This study reveals that NF‐κB1‐driven TRAIP upregulation in ALD correlates with disease severity. Mechanistically, TRAIP directly binds β‐catenin via its CC domain and promotes its K48‐linked ubiquitination and degradation, which is independent of the GSK3β/β‐TrCP pathway.
Zhan Wu   +13 more
wiley   +1 more source

Early Spatial and Contextual Coding Deficits in Hippocampal CA1 Precede Performance Decline in an Alzheimer's Disease Model

open access: yesAdvanced Science, EarlyView.
Two‐photon calcium imaging in behaving 5xFAD mice reveals early CA1 coding deficits before behavioral decline. Task‐related place cell activity and splitter cell trajectory coding are impaired, with reduced retrospective dominance and greater prospective weighting.
Yimei Li   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy